Stoke Therapeutics Inc diskutieren
Stoke Therapeutics Inc
WKN: A2PLTL / Symbol: STOK / Name: Stoke Therapeutics / Aktie / Biotechnologie & medizinische Forschung / ? /
11,10 €
-1,72 %
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $25.00 price target on the stock.
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $24.00 price target on the stock.
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) was upgraded by analysts at Bank of America Co. from an "underperform" rating to a "buy" rating.
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $25.00 price target on the stock.
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "outperform" rating re-affirmed by analysts at Credit Suisse Group AG. They now have a $23.00 price target on the stock.
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target lowered by analysts at Needham & Company LLC from $25.00 to $14.00. They now have a "buy" rating on the stock.
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target raised by analysts at Needham & Company LLC from $14.00 to $22.00. They now have a "buy" rating on the stock.
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) was upgraded by analysts at TD Cowen from a "market perform" rating to an "outperform" rating.
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target raised by analysts at Wedbush from $13.00 to $17.00. They now have an "outperform" rating on the stock.
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Ratings data for STOK provided by MarketBeat
Neueste Beiträge
DA_Davidson in eXp World Holdings diskutieren